Salud financiera de hoja de balance de LIDDS

Salud financiera controles de criterios 4/6

LIDDS tiene un patrimonio de los accionistas total de SEK13.9M y una deuda total de SEK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son SEK17.7M y SEK3.8M respectivamente.

Información clave

Ratio deuda-patrimonio

kr0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	kr13.51m
Patrimonio	kr13.90m
Total pasivo	kr3.76m
Activos totales	kr17.66m

Actualizaciones recientes sobre salud financiera

Recent updates

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

May 26

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Dec 15

Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?

Jul 19

Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn Situation

Mar 08

We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn Rate

Nov 23

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK15.9M) de LIDDS superan a sus pasivos a corto plazo (SEK3.8M).

Pasivo a largo plazo: LIDDS no tiene pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: LIDDS está libre de deudas.

Reducción de la deuda: LIDDS no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: LIDDS tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: LIDDS tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 7.4% cada año

Descubre empresas con salud financiera

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Salud financiera de hoja de balance de LIDDS

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?

Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn Situation

We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn Rate

Recent updates

LIDDS AB (publ), Annual General Meeting, May 27, 2024

LIDDS AB (publ) (OM:LIDDS) completed the acquisition of Noviga Research AB.

LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB.

LIDDS AB (publ) (OM:LIDDS) signed an agreement to acquire Noviga Research AB.

LIDDS AB (publ) Approves Board Elections

LIDDS AB (publ) to Report Fiscal Year 2023 Final Results on Apr 23, 2024

Lidds AB (Publ) Announces Resignation of Daniel Lifveredson from Board of Directors

LIDDS AB (publ) to Report Q1, 2024 Results on May 15, 2024

First half 2023 earnings released: kr0.29 loss per share (vs kr0.58 loss in 1H 2022)

LIDDS AB (publ) Announces CEO Changes

New major risk - Financial position

First quarter 2023 earnings released: kr0.29 loss per share (vs kr0.29 loss in 1Q 2022)

Full year 2022 earnings released: kr1.07 loss per share (vs kr1.16 loss in FY 2021)

LIDDS AB (publ) to Report Fiscal Year 2022 Results on Apr 25, 2023

Third quarter 2022 earnings released: kr0.23 loss per share (vs kr0.26 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.29 loss per share (vs kr0.32 loss in 2Q 2021)

LIDDS AB (publ) to Report Fiscal Year 2022 Results on Feb 24, 2023

High number of new directors

LIDDS AB (publ) Announces CEO Changes

LIDDS Patent Covering the NanoZolid® Production Process Granted in Israel

LIDDS AB (publ) Announces Board Changes

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

First quarter 2022 earnings: EPS and revenues miss analyst expectations

LIDDS AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

No independent directors

LIDDS AB (publ) announced that it expects to receive SEK 40.8 million in funding from Nice & Green SA

LIDDS AB Next Step with Nanozolid® Formulated Docetaxel

LIDDS AB Announces Positive Topline Results from the Phase I Dose-Escalating Study of NanoZolid-Formulated Docetaxel

Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation

Will LIDDS (STO:LIDDS) Spend Its Cash Wisely?

Here's Why We're Not Too Worried About LIDDS' (STO:LIDDS) Cash Burn Situation

Director recently bought kr159k worth of stock

LIDDS AB (publ) Enters R&D Agreement with Potential Exclusive, Global Product License Option

New 90-day low: kr13.50

LIDDS AB (publ) and Pharmidea Signs Manufacturing Agreement

LIDDS Files Patent Application for Method to Treat Brain Cancer with Intratumoral Depot Injections

LIDDS AB (publ) Provides Update on Chinese Conditional Market Approval (CMA) for Liproca® Depot

LIDDS AB (publ) Announces Management Changes, Effective April 19, 2021

We're Not Very Worried About LIDDS' (STO:LIDDS) Cash Burn Rate

New 90-day low: kr13.00

New 90-day low: kr13.10

LIDDS AB (publ) Announces Data on Liproca Depot from Open Label Extension Study

New 90-day high: kr16.15

LIDDS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 37.083996 million.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera